Literature DB >> 22842346

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.

Shigeki Chiba1, Muhammad Baghdadi, Hisaya Akiba, Hironori Yoshiyama, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Yoichiro Fujioka, Yusuke Ohba, Jacob V Gorman, John D Colgan, Mitsuomi Hirashima, Toshimitsu Uede, Akinori Takaoka, Hideo Yagita, Masahisa Jinushi.   

Abstract

The mechanisms by which tumor microenvironments modulate nucleic acid-mediated innate immunity remain unknown. Here we identify the receptor TIM-3 as key in circumventing the stimulatory effects of nucleic acids in tumor immunity. Tumor-associated dendritic cells (DCs) in mouse tumors and patients with cancer had high expression of TIM-3. DC-derived TIM-3 suppressed innate immune responses through the recognition of nucleic acids by Toll-like receptors and cytosolic sensors via a galectin-9-independent mechanism. In contrast, TIM-3 interacted with the alarmin HMGB1 to interfere with the recruitment of nucleic acids into DC endosomes and attenuated the therapeutic efficacy of DNA vaccination and chemotherapy by diminishing the immunogenicity of nucleic acids released from dying tumor cells. Our findings define a mechanism whereby tumor microenvironments suppress antitumor immunity mediated by nucleic acids.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842346      PMCID: PMC3622453          DOI: 10.1038/ni.2376

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  50 in total

1.  TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

Authors:  Yoshikane Kikushige; Takahiro Shima; Shin-ichiro Takayanagi; Shingo Urata; Toshihiro Miyamoto; Hiromi Iwasaki; Katsuto Takenaka; Takanori Teshima; Toshiyuki Tanaka; Yoshimasa Inagaki; Koichi Akashi
Journal:  Cell Stem Cell       Date:  2010-12-03       Impact factor: 24.633

Review 2.  HMGB1 is a therapeutic target for sterile inflammation and infection.

Authors:  Ulf Andersson; Kevin J Tracey
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

3.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

Authors:  Qing Zhou; Meghan E Munger; Rachelle G Veenstra; Brenda J Weigel; Mitsuomi Hirashima; David H Munn; William J Murphy; Miyuki Azuma; Ana C Anderson; Vijay K Kuchroo; Bruce R Blazar
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

4.  Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.

Authors:  Max Jan; Mark P Chao; Adriel C Cha; Ash A Alizadeh; Andrew J Gentles; Irving L Weissman; Ravindra Majeti
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

5.  Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.

Authors:  Yun Lin; Li Zhang; Ann X Cai; Mark Lee; Wandi Zhang; Donna Neuberg; Christine M Canning; Robert J Soiffer; Edwin P Alyea; Jerome Ritz; Nir Hacohen; Terry K Means; Catherine J Wu
Journal:  J Clin Invest       Date:  2011-03-14       Impact factor: 14.808

6.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

Authors:  Shin Foong Ngiow; Bianca von Scheidt; Hisaya Akiba; Hideo Yagita; Michele W L Teng; Mark J Smyth
Journal:  Cancer Res       Date:  2011-03-23       Impact factor: 12.701

7.  Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

Authors:  Mickaël Michaud; Isabelle Martins; Abdul Qader Sukkurwala; Sandy Adjemian; Yuting Ma; Patrizia Pellegatti; Shensi Shen; Oliver Kepp; Marie Scoazec; Grégoire Mignot; Santiago Rello-Varona; Maximilien Tailler; Laurie Menger; Erika Vacchelli; Lorenzo Galluzzi; François Ghiringhelli; Francesco di Virgilio; Laurence Zitvogel; Guido Kroemer
Journal:  Science       Date:  2011-12-16       Impact factor: 47.728

8.  Tim3 binding to galectin-9 stimulates antimicrobial immunity.

Authors:  Pushpa Jayaraman; Isabel Sada-Ovalle; Sarah Beladi; Ana C Anderson; Valerie Dardalhon; Chie Hotta; Vijay K Kuchroo; Samuel M Behar
Journal:  J Exp Med       Date:  2010-10-11       Impact factor: 14.307

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

View more
  295 in total

1.  Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function.

Authors:  Jacob V Gorman; John D Colgan
Journal:  Immunology       Date:  2018-02-08       Impact factor: 7.397

Review 2.  Post-translational modifications of high mobility group box 1 and cancer.

Authors:  Seidu A Richard; Yuanyuan Jiang; Lu Hong Xiang; Shanshan Zhou; Jia Wang; Zhaoliang Su; Huaxi Xu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

3.  TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.

Authors:  Álvaro de Mingo Pulido; Alycia Gardner; Shandi Hiebler; Hatem Soliman; Hope S Rugo; Matthew F Krummel; Lisa M Coussens; Brian Ruffell
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

4.  Interaction of TIM4 and TIM3 induces T helper 1 cell apoptosis.

Authors:  Rong-Ti Ge; Lu Zeng; Li-Hua Mo; Ling-Zhi Xu; Huan-Ping Zhang; Hai-Qiong Yu; Min Zhang; Zhi-Gang Liu; Zhan-Ju Liu; Ping-Chang Yang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

5.  Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

Authors:  Hyun-Bae Jie; Raghvendra M Srivastava; Athanassios Argiris; Julie E Bauman; Lawrence P Kane; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2017-04-13       Impact factor: 11.151

Review 6.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

7.  Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis.

Authors:  Xingwei Jiang; Tingting Zhou; Yan Xiao; Jiahui Yu; Shuaijie Dou; Guojiang Chen; Renxi Wang; He Xiao; Chunmei Hou; Wei Wang; Qingzhu Shi; Jiannan Feng; Yuanfang Ma; Beifen Shen; Yan Li; Gencheng Han
Journal:  Oncoimmunology       Date:  2016-08-03       Impact factor: 8.110

Review 8.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 10.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.